Hamilton Lane Advisors LLC Buys New Holdings in Caris Life Sciences, Inc. $CAI

Hamilton Lane Advisors LLC purchased a new position in Caris Life Sciences, Inc. (NASDAQ:CAI) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 58,725 shares of the company’s stock, valued at approximately $1,584,000. Caris Life Sciences makes up 0.9% of Hamilton Lane Advisors LLC’s holdings, making the stock its 13th largest holding.

Other institutional investors and hedge funds have also bought and sold shares of the company. Olistico Wealth LLC purchased a new stake in shares of Caris Life Sciences in the 4th quarter valued at $31,000. Diversified Trust Co. acquired a new position in Caris Life Sciences during the fourth quarter valued at $540,000. Finally, Zevenbergen Capital Investments LLC purchased a new stake in Caris Life Sciences in the fourth quarter valued at $14,655,000.

Caris Life Sciences Price Performance

CAI stock opened at $19.29 on Friday. The stock has a market capitalization of $5.45 billion and a PE ratio of -107.17. The stock’s 50-day moving average is $20.19. The company has a quick ratio of 7.35, a current ratio of 7.85 and a debt-to-equity ratio of 0.66. Caris Life Sciences, Inc. has a 52 week low of $16.28 and a 52 week high of $42.50.

Caris Life Sciences (NASDAQ:CAI) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.27. The company had revenue of $292.89 million during the quarter, compared to analysts’ expectations of $281.00 million. During the same period in the prior year, the business posted ($1.73) earnings per share. The company’s quarterly revenue was up 125.4% compared to the same quarter last year.

Wall Street Analysts Forecast Growth

CAI has been the subject of several analyst reports. Evercore set a $38.00 price objective on Caris Life Sciences in a report on Monday, January 5th. BTIG Research reduced their price target on Caris Life Sciences from $45.00 to $38.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Wall Street Zen raised Caris Life Sciences from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Canaccord Genuity Group dropped their price objective on shares of Caris Life Sciences from $30.00 to $22.00 and set a “hold” rating on the stock in a research note on Friday, March 13th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Caris Life Sciences in a report on Monday, December 29th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $30.60.

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.